CLINICAL_TRIALS ClinicalTrials.gov record update

YUflyma® (Adalimumab), Patient Experience After Switching to adaliMumab biosimilAr High concenTration, Low Volume (40mg/0.4mL) (Yuflyma®) by Taking Patient pERception of Treatment Into Account: The YU-MATTER Study

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05427942
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:36.876850+00:00
Published At: 2022-06-22T00:00:00+00:00
Record Updated At: 2022-06-22
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Rheumatoid Arthritis", "Ankylosing Spondylarthritis", "Axial Spondyloarthritis Without Radiographic Evidence of Ankylosing Spondylitis", "Psoriatic Arthritis", "Crohn Disease", "Ulcerative Colitis"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2022-06-22"
protocolSection.identificationModule.nctId: "NCT05427942"
protocolSection.identificationModule.officialTitle: "YUflyma\u00ae (Adalimumab), Patient Experience After Switching to adaliMumab biosimilAr High concenTration, Low Volume (40mg/0.4mL) (Yuflyma\u00ae) by Taking Patient pERception of Treatment Into Account: The YU-MATTER Study"
protocolSection.statusModule.overallStatus: "UNKNOWN"
protocolSection.designModule.phases: []
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.